3CDS
 
 | |
5H8X
 | | Crystal structure of the complex MMP-8/BF471 (catechol inhibitor) | | Descriptor: | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, CALCIUM ION, Neutrophil collagenase, ... | | Authors: | Pochetti, G, Montanari, R, Capelli, D, Tortorella, P. | | Deposit date: | 2015-12-24 | | Release date: | 2016-11-02 | | Last modified: | 2024-01-10 | | Method: | X-RAY DIFFRACTION (1.3 Å) | | Cite: | Catechol-based matrix metalloproteinase inhibitors with additional antioxidative activity.
J Enzyme Inhib Med Chem, 31, 2016
|
|
3CDP
 | | Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid | | Descriptor: | (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid, Peroxisome proliferator-activated receptor gamma | | Authors: | Pochetti, G, Montanari, R, Mazza, F. | | Deposit date: | 2008-02-27 | | Release date: | 2009-01-13 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors alpha/gamma dual agonists
Bioorg.Med.Chem., 20, 2012
|
|
4JAZ
 | | Crystal structure of the complex between PPARgamma LBD and trans-resveratrol | | Descriptor: | Peroxisome proliferator-activated receptor gamma, RESVERATROL | | Authors: | Pochetti, G, Capelli, D, Montanari, R, Calleri, E, Moaddel, R, Temporini, C. | | Deposit date: | 2013-02-19 | | Release date: | 2014-02-12 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (2.85 Å) | | Cite: | Resveratrol and Its Metabolites Bind to PPARs.
Chembiochem, 15, 2014
|
|
4QKZ
 | | X-ray structure of the catalytic domain of MMP-8 with the inhibitor ML115 | | Descriptor: | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, CALCIUM ION, Neutrophil collagenase, ... | | Authors: | Pochetti, G, Montanari, R, Capelli, D, Tortorella, P. | | Deposit date: | 2014-06-10 | | Release date: | 2015-06-17 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (1.2 Å) | | Cite: | Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy.
Pharmaceuticals, 13, 2020
|
|
